KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash & Equivalents (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Cash & Equivalents for 16 consecutive years, with $44.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 32.73% to $44.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.3 million through Dec 2025, down 32.73% year-over-year, with the annual reading at $44.3 million for FY2025, 32.73% down from the prior year.
  • Cash & Equivalents hit $44.3 million in Q4 2025 for Inovio Pharmaceuticals, up from $36.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $83.6 million in Q1 2021 to a low of $14.3 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $42.5 million across 5 years, with a median of $40.5 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: plummeted 72.65% in 2021 and later soared 359.88% in 2024.
  • Year by year, Cash & Equivalents stood at $71.1 million in 2021, then crashed by 34.88% to $46.3 million in 2022, then crashed by 69.11% to $14.3 million in 2023, then skyrocketed by 359.88% to $65.8 million in 2024, then crashed by 32.73% to $44.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for INO at $44.3 million in Q4 2025, $36.6 million in Q3 2025, and $24.4 million in Q2 2025.